NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
Go back to NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer| (NASDAQ: NBP) | Delayed: 1.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.77 | 52 Week High | $6.95 | |||
| Open | $1.77 | 52 Week Low | $6.95 | |||
| Day High | $1.77 | P/E | 0.83 | |||
| Day Low | $1.77 | EPS | $2.14 | |||
| Volume | 343 | |||||
